Session Information
Date: Tuesday, September 24, 2019
Session Title: Parkinsonisms and Parkinson-Plus
Session Time: 1:45pm-3:15pm
Location: Agora 3 West, Level 3
Objective: This large prospective longitudinal cohort aims to identify nature history of a highly-presentative Chinese PD population and to discern clinical and genetic markers which indicates disease progression.
Background: Parkinson’s disease (PD) is a clinically and genetically neurodegenerative disease which characterized by motor symptoms and nonmotor symptoms. Long-term treatment strategy for different individuals, including pharmacies, behavioral and surgical therapy may complicate its natural history.
Method: The Chinese Parkinson’s disease Registry (CPDR) was carried out from February 2017 and will prospectively collect information every year in the following 10 years. Clinically esablished PD and probable PD were consecutively recruited according to the Movement Disorder Society Clinical Diagnostic Criteria for PD. Data were collected at baseline and 12±1 month. All the participants are scanned by structural MRI to exclude obvious intracranial lesions and other parkinsonism such as MSA, PSP and WD. Information of demographic information, living habits and toxic exposure history were recorded at baseline. The Unified Parkinson’s Disease Rating Scale (UPDRS) is conducted for motor assessment, all the patients are evaluated in “OFF” state. The clinical stage of PD is assessed by Hoehn and Yahr scale. The non-motor symptoms are evaluated by Autonomic Symptoms, Functional Constipation Diagnostic Criteria Rome III, PDQ-39, Parkinson’s Disease Sleep Scale, Epworth Sleepiness Scale, RBDQ-Hongkong, Cambridge Hopkins Restless Leg syndrome questionnaire, Mini Mental State Examination, Hyposmia Rating Scale, Hamilton Depression Scale, PD fatigue severity scale. Motor complications were evaluated by Wearing-off questionnaire-9, new freezing gait questionnaire scores and UPDRS IV. DNA samples extracted from peripheral blood and all the PD patients will be examed by Whole Exome Sequencing or Whole-genome sequencing.
Results: From 01 February 2017 to 31 December 2018, 3223 consecutive PD patients were recruited which compromised the CPDR cohort. 946 PD patients accomplished the first follow-up according to the scheme.
Conclusion: CPDR is a large prospective longitudinal cohort aims to identify nature history of Chinese PD which paves way for understanding the natural history and clinical and genetic markers for PD.
To cite this abstract in AMA style:
XT. Zhou, XX. Zhou, YW. Zhao, LX. Qin, Q. Xu, Y. Tian, LJ. Fang, ZQ. Wang, QY. Sun, JC. Li, JF. Guo, XX. Yan, BS. Tang. The Chinese Parkinson’s disease Registry scheme [abstract]. Mov Disord. 2019; 34 (suppl 2). https://www.mdsabstracts.org/abstract/the-chinese-parkinsons-disease-registry-scheme/. Accessed November 21, 2024.« Back to 2019 International Congress
MDS Abstracts - https://www.mdsabstracts.org/abstract/the-chinese-parkinsons-disease-registry-scheme/